The University of Dublin | Trinity College -- Ollscoil Átha Cliath | Coláiste na Tríonóide
Trinity's Access to Research Archive
Home :: Log In :: Submit :: Alerts ::

School of Medicine >
Pharmacology & Therapeutics >
Pharmacology & Therapeutics (Scholarly Publications) >

Please use this identifier to cite or link to this item:

Title: Glutamate receptors in preclinical research on Alzheimer's disease: update on recent advances
Sponsor: Health Research Board
Science Foundation Ireland
Author's Homepage:
Keywords: Pharmacology
Alzheimer's disease
Issue Date: 2012
Publisher: Elsevier
Citation: Neng-Wei Hu, Tomas Ondrejcak, Michael J. Rowan, Glutamate receptors in preclinical research on Alzheimer's disease: update on recent advances, Pharmacology, 100, 4, 2012, 855 862
Series/Report no.: Pharmacology;
Abstract: The cognitive and related symptoms of Alzheimer's disease are mainly attributable to synaptic failure. Here we review recent research on how the Alzheimer's disease amyloid ß-protein (Aß) affects glutamate receptors and fast excitatory synaptic transmission and plasticity of that transmission. L-glutamate, the main excitatory neurotransmitter in the brain, has long been implicated in causing NMDA receptor-mediated excitotoxicity leading to neurodegeneration in the late stages of the disease. However there is now extensive evidence that soluble Aß oligomers disrupt synaptic transmission and especially synaptic plasticity via non-excitotoxic glutamatergic mechanisms. New data highlight the relatively selective involvement of certain glutamate receptor subtypes including GluN2B (NR2B) subunit-containing NMDA receptors and mGlu5 receptors. Aß exerts direct and indirect effects on synaptic plasticity-related glutamate receptor signaling and trafficking between different neuronal compartments. For example, Aß-induced ectopic NMDA and mGlu receptor-mediated signaling coupled with caspase-3 activation may cause inhibition of long-term potentiation and facilitation of long-term depression. Intriguingly, some of the disruptive synaptic actions of Aß have been found to be dependent on endogenous tau located in dendrites or spines. Given the role of glutamatergic transmission in regulating Aß production and release, future therapies targeting glutamate offer the opportunity to remedy both mis-processing of Aß and cellular mechanisms of synaptic failure in early AD.
Description: PUBLISHED
Related links:
Appears in Collections:Pharmacology & Therapeutics (Scholarly Publications)

Files in This Item:

File Description SizeFormat
Glutamate receptors in preclinical research on Alzheimer's disease- update on recent advances.pdfPublished (author's copy) - Peer Reviewed457.36 kBAdobe PDFView/Open

This item is protected by original copyright

Please note: There is a known bug in some browsers that causes an error when a user tries to view large pdf file within the browser window. If you receive the message "The file is damaged and could not be repaired", please try one of the solutions linked below based on the browser you are using.

Items in TARA are protected by copyright, with all rights reserved, unless otherwise indicated.


Valid XHTML 1.0! DSpace Software Copyright © 2002-2010  Duraspace - Feedback